TABLE 2. Seroprotection rates and geometric mean titers for inactivated Vero cell culture–derived Japanese encephalitis vaccine administered to adults aged 18–65 years in an accelerated schedule with rabies vaccine or standard schedule with and without rabies vaccine*.
| Measure and time after second JE-VC dose | Primary series schedule |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| JE-VC, 0 and 7 days with rabies
vaccine† |
JE-VC, 0 and 28 days with rabies
vaccine§ |
JE-VC, 0 and 28 days alone |
|||||||
|
Seroprotection
rate¶
|
Total
|
No.
seroprotected
|
(%)
|
Total
|
No.
seroprotected
|
(%)
|
Total
|
No.
seroprotected
|
(%)
|
| 28 days |
206
|
203 |
99 |
157
|
157 |
100 |
49
|
49 |
100 |
| >300
days** |
199
|
188 |
94 |
154
|
132 |
86 |
48
|
42 |
88 |
|
GMT††
|
GMT (95%
CI)
|
GMT (95%
CI)
|
GMT (95%
CI)
|
||||||
| 28 days |
690
(595‒801) |
299
(254‒352) |
337
(252‒451) |
||||||
| >300 days** | 117
(100‒137) |
39
(33‒47) |
39
(28‒54) |
||||||
Sources: Food and Drug Administration. Ixiaro: Japanese encephalitis vaccine, inactivated, adsorbed [package insert]. Vienna, Austria: Valneva Austria GmbH; 2018. https://www.fda.gov/media/75777/download; Jelinek T, Burchard GD, Dieckmann S, et al. Short-term immunogenicity and safety of an accelerated pre-exposure prophylaxis regimen with Japanese encephalitis vaccine in combination with a rabies vaccine: A phase III, multicenter, observer-blind study. J Travel Med 2015;22:225–31; Cramer JP, Jelinek T, Paulke-Korinek M, et al. One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series. J Travel Med 2016;23:1–8.
Abbreviations: CI = confidence interval; GMT = geometric mean titer; JE-VC = Vero cell culture–derived Japanese encephalitis vaccine; PCEC = purified chick embryo cell.
* Per-protocol analysis.
† PCEC rabies vaccine administered in a 0-, 3-, 7-day schedule.
§ PCEC rabies vaccine administered in a 0-, 7-, 28-day schedule.
¶ Proportion with 50% plaque reduction neutralization test titer ≥10.
** Study ended on day 365.
†† PRNT titers <10 were imputed to 5.